netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.02  Expand sub section  Diuretics
02.02.01  Expand sub section  Thiazides and related diuretics
Indapamide
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets

First choice for hypertension, where a thiazide is indicated (see NICE CG127: Hypertension).

N.B. Modified release tablets are NON-formulary 
Bendroflumethiazide
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice Tablets

Not first line for hypertension (see NICE CG127: Hypertension). Patients with stable and controlled blood pressure currently taking bendroflumethiazide can continue treatment.

 
   
Metolazone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green 3
Tablets

unlicensedunlicensed
UK licensed product discontinued in 2012. Unlicensed import product is available from Pharmacy.

 
   
Chlorothiazide
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Suspension

unlicensedunlicensed


Restricted ItemPaediatric use only 
   
02.02.02  Expand sub section  Loop diuretics
Furosemide
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets
Liquid
Injection

 
Bumetanide
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice Tablets
Liquid

Injection has been discontinued

 
   
Torasemide
View adult BNF View SPC online View childrens BNF  Track Changes
Third Choice Tablets 
   
02.02.03  Expand sub section  Potassium-sparing diuretics and aldosterone antagonists
Amiloride
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets
Liquid

 
   
02.02.03  Expand sub section  Aldosterone antagonists to top
Spironolactone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets
Suspension

Spironolactone is significantly cheaper than eplerenone but there is no data available to compare cost-effectivess in particular groups of patients.  
Link  MHRA Safety Alert: Risk of potentially fatal hyperkalaemia
   
Eplerenone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets

 
Link  Link to GMMMG IPNTS recommendation: Eplerenone
Link  NICE CG172 MI secondary prevention: Secondary prevention in primary and secondary care for patients following a myocardial infarction
   
02.02.04  Expand sub section  Potassium-sparing diuretics with other diuretics
Co-amilofruse (amiloride and furosemide)
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice Tablets
Although it is preferable to prescribe potassium-sparing diuretics and loop diuretics separately, the use of fixed combinations may be justified if compliance is a problem (BNF).  
   
Co-amilozide
View adult BNF View SPC online View childrens BNF  Track Changes
Second Choice Tablets
Although it is preferable to prescribe potassium-sparing diuretics and thiazide diuretics separately, the use of fixed combinations may be justified if compliance is a problem (BNF).  
   
02.02.05  Expand sub section  Osmotic diuretics
Mannitol
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Intravenous Infusion 
   
02.02.06  Expand sub section  Mercurial diuretics
02.02.07  Expand sub section  Carbonic anhydrase inhibitors
02.02.08  Expand sub section  Diuretics with potassium to top
 ....
 Non Formulary Items
Burinex K

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
 
Centyl K

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
 
Chlortalidone

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Co-flumactone

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Co-triamterzide

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cyclopenthiazide  (Navidrex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Diumide-K Continus

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
 
Frusene

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Hydrochlorothiazide

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Indapamide  (Modified Release )

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary Modified Release Tablets

 
Kalspare

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Lasikal

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
 
Navispare

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Neo-NaClex-K

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
 
Triamterene  (Dytac®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Xipamide  (Diurexan®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary